Eli Lilly and Co.'s combination of chemotherapy and Cyramza was more successful than chemo-plus-placebo in slowing progression of bladder cancer among patients previously treated with platinum-based chemo, according to results presented at the European Society for Medical Oncology in Madrid. The Cyramza combo was associated with 46% prolonged progression-free survival of 4.07 months.
Cyramza-chemo combo makes inroads against bladder cancer
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.